| Full text | |
| Author(s): |
Evangelista, Andreia Silva
;
Nakhle, Maria Cristina
;
de Araujo, Thiago Ferreira
;
Abrantes-Lemos, Clarice Pires
;
Deguti, Marta Mitiko
;
Carrilho, Flair Jose
;
Rachid Cancado, Eduardo Luiz
Total Authors: 7
|
| Document type: | Journal article |
| Source: | BIOMED RESEARCH INTERNATIONAL; v. 2015, p. 8-pg., 2015-01-01. |
| Abstract | |
Iron abnormalities in chronic liver disease may be the result of genetic diseases or secondary factors. The present study aimed to identify subjects with HFE-HH in order to describe the frequency of clinical manifestations, identify risk factors for iron elevation, and compare the iron profile of HFE-HH to other genotypes in liver disease patients. A total of 108 individuals with hepatic disease, transferrin saturation (TS) > 45%, and serum ferritin (SF) > 350 ng/mL were tested for HFE mutations. Two groups were characterized: C282Y/C282Y or C282Y/H63D genotypes (n = 16) were the HFE hereditary hemochromatosis (HFE-HH) group; and C282Y and H63D single heterozygotes, the H63D/H63D genotype, and wild-type were considered group 2 (n = 92). Nonalcoholic liver disease, alcoholism, and chronic hepatitis C were detected more frequently in group 2, whereas arthropathy, hepatocarcinoma, diabetes, and osteoporosis rates were significantly higher in the HFE-HH group. TS > 82%, SF > 2685 ng/mL, and serum iron > 178 mu g/dL were the cutoffs for diagnosis of HFE-HH in patients with liver disease. Thus, in non-Caucasian populations with chronic liver disease, HFE-HH diagnosis is more predictable in those with iron levels higher than those proposed in current guidelines for the general population. (AU) | |
| FAPESP's process: | 09/53946-3 - Acquisition of a genetic analyzer for automated DNA sequencing |
| Grantee: | João Renato Rebello Pinho |
| Support Opportunities: | Multi-user Equipment Program |